1. Home
  2. SCM vs ACIU Comparison

SCM vs ACIU Comparison

Compare SCM & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Stellus Capital Investment Corporation

SCM

Stellus Capital Investment Corporation

HOLD

Current Price

$8.74

Market Cap

244.3M

Sector

Finance

ML Signal

HOLD

Logo AC Immune SA

ACIU

AC Immune SA

HOLD

Current Price

$2.69

Market Cap

247.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SCM
ACIU
Founded
2012
2003
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
244.3M
247.6M
IPO Year
2012
2015

Fundamental Metrics

Financial Performance
Metric
SCM
ACIU
Price
$8.74
$2.69
Analyst Decision
Hold
Strong Buy
Analyst Count
1
2
Target Price
$9.00
$10.00
AVG Volume (30 Days)
174.1K
223.6K
Earning Date
05-11-2026
05-12-2026
Dividend Yield
14.22%
N/A
EPS Growth
N/A
N/A
EPS
0.62
N/A
Revenue
N/A
N/A
Revenue This Year
$0.33
$706.75
Revenue Next Year
N/A
$321.13
P/E Ratio
$14.08
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.83
$2.04
52 Week High
$14.85
$4.00

Technical Indicators

Market Signals
Indicator
SCM
ACIU
Relative Strength Index (RSI) 59.38 57.07
Support Level $8.43 $2.57
Resistance Level $8.97 $3.13
Average True Range (ATR) 0.20 0.17
MACD 0.00 0.02
Stochastic Oscillator 48.94 55.46

Price Performance

Historical Comparison
SCM
ACIU

About SCM Stellus Capital Investment Corporation

Stellus Capital Investment Corp is a closed-end, non-diversified management investment company. Its objective is to maximize the total return to its stockholders in the form of current income and capital appreciation. It invests in private middle-market companies through first lien, second lien, and unsecured debt financing, often with a corresponding equity investment. The company invests in various sectors, such as business services, energy, general industrial, government services, healthcare, software, and specialty finance. The business activity of the firm functions throughout the United States, and it generates revenue in the form of interest income on debt investments, capital gains, and distributions.

About ACIU AC Immune SA

AC Immune SA is a clinical stage biopharmaceutical company advancing a portfolio of programs strategically focused on pioneering Precision Medicine for neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company has one segment. The company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.

Share on Social Networks: